The Technical Analyst
Select Language :
Celyad SA [CYAD]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Celyad SA Price, Forecast, Insider, Ratings, Fundamentals & Signals

Celyad SA is listed at the  Exchange

-12.96% $0.470

America/New_York / 18 mai 2023 @ 16:00


FUNDAMENTALS
MarketCap: 14.24 mill
EPS: -1.470
P/E: -0.320
Earnings Date: Mar 23, 2023
SharesOutstanding: 30.29 mill
Avg Daily Volume: 0.0181 mill
RATING 2023-05-18
A-
Buy
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Neutral
Return On Asset: Strong Buy
DE: Sell
P/E: Neutral
Price To Book: Sell
QUARTER GROWTHS
3/214/211/222/224/224/22
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/an/a
Ebitn/an/a
Asset n/a
Debtn/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.320 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.05x
Company: PE -0.320 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 0.367 - 0.573

( +/- 21.91%)
ATR Model: 14 days

Forecast: 01:40 - $0.678

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $0.470 (-12.96% )
Volume 0.0490 mill
Avg. Vol. 0.0181 mill
% of Avg. Vol 271.35 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Celyad SA

Last 12 Months

Last 12 months chart data with high, low, open and close for Celyad SA

RSI

Intraday RSI14 chart for Celyad SA

Last 10 Buy & Sell Signals For CYAD

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Celyad SA

CYAD

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Last 10 Buy Signals

Date Signal @
PEPECOINUSDMar 29 - 02:245.83
VRXUSDMar 29 - 02:1960.44
^N300Mar 29 - 02:00594.52
CBKUSDMar 29 - 02:151.087
ORCAUSDMar 29 - 02:153.83
TRXUSDMar 29 - 02:10$0.120
BADGERUSDMar 29 - 02:117.11
INDEXUSDMar 29 - 02:085.97
FUMOUSDMar 29 - 02:109 998.30
FTNUSDMar 29 - 02:101.819

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.